GATA3 and breast cancer: In our previous work11, we expressed GATA3 at physiologic levels in a GATA3-negative breast cancer cell line, tracking GATA3 binding across the genome by chromatin immunoprecipitation-sequencing (ChIP-seq) and chromatin accessibility using the assay for transposase-accessible chromatin using sequencing (ATAC-seq).